# **Interaction between the GAGA factor and Mod(mdg4) proteins promotes insulator bypass in Drosophila**

# Larisa Melnikova\*<sup>†</sup>, François Juge<sup>†‡</sup>, Natalia Gruzdeva\*, Aleksandr Mazur\*<sup>§</sup>, Giacomo Cavalli<sup>‡¶</sup>, and Pavel Georgiev\*<sup>¶</sup>

\*Department of the Control of Genetic Processes, Institute of Gene Biology, Russian Academy of Sciences, Moscow 117334, Russia; ‡Institute of Human Genetics, Centre National de la Recherche Scientifique, 141 Rue de la Cardonille, 34396 Montpellier Cedex 5, France; and <sup>§</sup>Institute of Physics and Technology, Dolgoprudnii Town, Moscow 141700, Russia

Edited by Gary Felsenfeld, National Institutes of Health, Bethesda, MD, and approved August 28, 2004 (received for review June 3, 2004)

**Chromatin insulators or boundaries are proposed to structure the chromatin fiber into functionally independent domains by promoting the formation of chromatin loops. These elements can block the communication between an enhancer and a gene when placed between them. Interestingly, it has been previously observed that two tandem copies of the** *Drosophila* **Su(Hw) insulator abolish this enhancer-blocking activity, presumably through pairing. This bypass effect has not been described with other insulators, however. In this report, we show that the insertion of binding sites for the GAGA factor (GAF) between an enhancer and the Su(Hw) insulator allows bypassing of the insulator. This bypass relies on the activity of both the GAF protein and the Mod(mdg4)-67.2 protein, a factor required for Su(Hw) insulator activity. We show that these two proteins interact** *in vitro* **and** *in vivo***, providing molecular evidence of pairing between the GAF sites and the Su(Hw) insulator. Finally, we show that placing the** *Mcp* **boundary together with the Su(Hw) insulator between an enhancer and a promoter leads to bypass, again in a GAF- and Mod(mdg4)-dependent manner. Our data provide direct evidence that heterologous insulators can be bypassed by distal enhancers and identify the interaction between GAF and Mod(mdg4) as a possible means to regulate insulator activity.**

**I** nsulators and boundaries are chromosomal elements that have been proposed to be involved in the establishment of indebeen proposed to be involved in the establishment of independent domains within the chromatin fiber. By preventing interactions between regulatory sequences in one domain and promoters in other domains, they participate in the regulation of enhancer/promoter communication. These elements have been experimentally defined by two types of activities, as evidenced by different assays. The first activity can block the communication between an enhancer and a promoter when the insulator is inserted between them (enhancer-blocking activity). The second activity can protect transgenes from position effects and can act as a barrier to the spread of repressive heterochromatin (barrier activity). Numerous insulators have been described in species ranging from yeast to mammals, and some of them contain both enhancer-blocking and barrier activities (reviewed in ref. 1).

Recent data suggest that the establishment of independent loop domains in chromatin can be mediated by interactions between insulators and/or by the tethering of insulators to the nuclear matrix or nuclear envelope. For example, in *Drosophila*, the scs and scs insulators flanking the 15-kb *hsp70* region have been shown to be in close proximity to each other in embryonic cells. This pairing seems to be mediated by interactions between the scs-binding protein Zw5 and the scs'-binding protein boundary element-associated factor (BEAF) (2). In yeast, a screen for proteins with boundary activity identified several proteins that interact with the nuclear pore complex (NPC), and tethering of the *HML* locus to the NPC has been shown to block the spread of repression (3). Finally, the CCCTC-binding factor (CTCF) protein, which binds insulators in the  $\beta$ -globin locus in chickens, mice, and humans, can target an insulator to the nucleolar surface (4).

Strong evidence for the role of insulators in creating loop domains comes from several studies of the *Drosophila* Su(Hw) insulator. This insulator, originally identified within the *gypsy* retrotransposon, contains 12 binding sites for the DNA-binding protein Su(Hw) (5). Su(Hw) interacts with an isoform of the Mod(mdg4) protein, a BTB/POZ (*broad complex*, *tramtrack*, and *brick à brack*/poxviruses and zinc finger) domain-containing protein, and both proteins are required for insulator function *in vivo* (6). Su(Hw) and Mod(mdg4) are associated with  $>$ 200 loci on polytene chromosomes (7). In diploid cells, however, these proteins form only 20–25 foci per cell nucleus, called insulator bodies, suggesting that several insulators coalesce into higherorder structures (7). Moreover, when two Su(Hw) insulators are inserted in tandem between an enhancer and a promoter, communication between the sequences located outside the domain bordered by the insulators is permitted, allowing the enhancer to bypass the insulators and activate the promoter (8, 9). These results suggest that two insulators positioned in tandem may loop out the sequences between them, bringing the enhancer and promoter into close proximity. Finally, treatment of *Drosophila* nuclei with 2 M NaCl to unravel chromatin (halo technique) can be used to reveal chromosomal loops attached to the nuclear matrix, and insertion of a *gypsy* element into one of these loops induces its subdivision into two smaller loops (10). This evidence indicates that the Su(Hw) insulator is involved in the establishment and the anchoring of loops to the nuclear matrix.

Several other boundaries and insulators have been described in *Drosophila*: the *Mcp* and *Fab-7* boundaries of the Bithorax complex (BX-C) (reviewed in ref. 11), the SF1 boundary (12), the *even-skipped* (*eve*) promoter (13), and two regions in the  $\alpha$ 1-tubulin gene (14). These elements have not been shown to be involved in the creation of loop domains, although long-distance interactions between two *Mcp* elements and between two *Fab-7* elements located in transgenes inserted on different chromosomes have been observed, suggesting that these elements might be capable of structuring chromosomal domains (15, 16). Interestingly all of these insulators and boundaries include binding sites for the GAGA factor (GAF) protein in their sequence, and several of them are regulated and bound by GAF *in vivo* (13, 17–20). GAF-binding sites are required for the insulator function of both the *eve* promoter (13) and the SF1 boundary (12). In addition, mutations in the *Trithorax-like* (*Trl*) gene, which encodes GAF (21), impair the enhancer-blocking activity of these insulators (12, 13).

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: PTS, promoter-targeting sequence; BX-C, Bithorax complex; GAF, GAGA factor; *Trl*, *Trithorax-like*; Ee, eye enhancer; Y, *yellow* marker gene; S, Su(Hw) insulator; W, *miniwhite*; G, GAF array; BTB, *broad complex*, *tramtrack*, and *brick a` brack*.

<sup>†</sup>L.M. and F.J. contributed equally to this work.

<sup>1</sup>To whom correspondence may be addressed. E-mail: georgiev\_p@mail.ru or giacomo.cavalli@igh.cnrs.fr.

<sup>© 2004</sup> by The National Academy of Sciences of the USA

GAF is a DNA-binding protein that is involved in the regulation of numerous genes in *Drosophila* and can participate in gene activation as well as gene repression (reviewed in ref. 22). In particular, GAF is involved in creating nucleosome-free regions by interacting with complexes involved in nucleosome remodeling, as exemplified by its role on the heat shock genes *hsp70* and *hsp26* (reviewed in ref. 23). All GAF isoforms produced *in vivo* contain a BTB domain in their N-terminal part (24). The BTB domain [also called POZ (poxviruses and zinc finger) domain] is found in numerous proteins, including transcription factors and actin-binding proteins, and constitutes a protein–protein interaction motif involved in homo- or heterodimer formation (reviewed in ref. 25). The presence of a BTB domain in GAF and Mod(mdg4) proteins is one of the rare common features that has been found in proteins that bind insulators. Interestingly, a genetic interaction between *Trl* and *mod(mdg4*) mutants has been described, and both proteins colocalize partially on polytene chromosomes (7), suggesting that they may interact.

Indeed, we describe here that GAF and Mod(mdg4) proteins interact *in vivo* and *in vitro*. Moreover, we show that inserting either an array of GAF-binding sites or the *Mcp* boundary between an enhancer and the Su(Hw) insulator neutralizes the enhancer-blocking activity of the insulator and promotes insulator bypass. In both cases, this neutralization requires the activity of both Mod(mdg4) and GAF proteins. These results suggest that a loop domain is formed between the element bound by GAF and that bound by Mod(mdg4), and that the interaction between these two elements cancels the enhancer-blocking activity of the Su(Hw) insulator and restores the communication between an upstream enhancer and a downstream reporter gene.

### **Methods**

**Transgenic Constructs.** The 430-bp Su(Hw) insulator was PCRamplified from the *gypsy* retrotransposon and inserted between two loxP sites. An 8-kb fragment containing the *yellow* gene was provided by P. Geyer (University of Iowa, Iowa City). The *white* regulatory sequences from positions  $-1084$  to  $-1465$  bp relative to the transcription start site, containing the eye enhancer (Ee), were cloned between two frt sites [frt(Ee)]. The Ee or frt(Ee) fragment was inserted between body and wing enhancers at position 1868 relative to the *yellow* transcription start site. A 690-bp *Sal*I-*Pst*I fragment containing the *Mcp* fragment was inserted in direct orientation at position  $-893$  relative to the *yellow* transcription start site. The eight GAF-binding sites obtained by duplication of the 76-bp DNA fragment containing four binding sites from the *hsp70* promoter region (between primers 5'-ATTCGTTATTCTCTC and 5'-GTTTACTGTGT-GAC) were cloned between loxP or frt sites. For details of the different subcloning steps, see *Supporting Methods*, which is published as supporting information on the PNAS web site. Transgenic flies were obtained by standard methods. For details of the crosses for genetic experiments, see *Supporting Methods*. All frt- and loxP-dependent excisions of specific elements were verified by genomic PCR experiments.

**Immunoprecipitations and Nuclear Matrix Preparation.** Immunoprecipitation (IP) experiments were performed from *Drosophila* SL-2 cell nuclear extracts, prepared with the Nuclear Extract Kit (Active Motif). Nuclear extract  $(100 \mu g)$  was incubated overnight at 4°C with the sera or preimmune sera (1–2% volume) in the presence of protein  $A/G$  plus agarose (Santa Cruz Biotechnology) in 200  $\mu$ l of a buffer (25 mM Hepes/100 mM KCl/5 mM  $\text{MgCl}_2/10\%$  glycerol/0.1% Triton X-100/1 mM DTT/1% BSA). Beads were then washed four times in the same buffer without BSA, containing 100 mM KCl for the experiment of Fig. 1*A* and 300 mM KCl for the experiment of Fig. 1*B*. The sera used for IPs and Western blots were as follows. For GAF, we generated a



**Fig. 1.** GAF and Mod(mdg4) coimmunoprecipitate and are present in the nuclear matrix. (*A* and *B*) Coimmunoprecipitation experiments. The serum used for the immunoprecipitation is indicated above each lane. PI indicates that the PreImmune serum was used. Western blots were probed with the anti-Mod(mdg4) serum (*A*) or the anti-GAF serum (*B*). (*C*) Nuclear matrix analysis. The different fractions correspond to the different steps of the nuclear matrix extraction, according to the original protocol (27). N, nuclei; DN, nuclei digested with DNase I and RNase A; NS, nuclease supernatant; TXS, supernatant after Triton X-100 treatment; SS1, first salt supernatant; SS2, second salt supernatant; DSNF-I, *Drosophila* subnuclear fraction I, which contains nuclear lamina, pore complexes, and the nuclear matrix. Antibodies against GAF, Mod(mdg4), lamin, and Ubx proteins were used to probe the different fractions as indicated.

rabbit antiserum directed against the full-length GAF-519, bacterially expressed and purified through a Histidine-tag (26). The polyhomeotic (PH) antibody was provided by F. Maschat (Institute of Human Genetics, CNRS, Montpellier, France). For Mod(mdg4), a serum directed against the BTB domain was provided by R. Dorn (Martin Luther University, Halle, Germany). A monoclonal anti-Ubx antibody was provided by Y. Graba (Laboratoire de Génétique et Biologie du Développement, Institut de Biologie du Développement de Marseille, CNRS, Marseille, France), and a monoclonal anti-lamin antibody was provided by D. Arndt-Jovin (Max Planck Institute for Biophysical Chemistry, Göttingen, Germany). The nuclear matrix was prepared according to Fisher and Blobel (27) from 0- to 24-h-old *Drosophila* embryos. Western blots were performed following standard protocols.

**In Vitro and Two-Hybrid Interactions.** GST-Mod(mdg4)-67.2 (28) and His-tagged-GAF (26) were expressed in BL21(DE3) and purified on Glutathione Sepharose 4B (Amersham Pharmacia Biosciences) or nickel-nitrilotriacetic acid (Ni-NTA) agarose (Qiagen, Valencia, CA), respectively. *In vitro* translations were performed with TNT Coupled Reticulocyte Lysate Systems (Promega) with 35S-labeled methionine and cysteine (Redivue pro-mix, Amersham Pharmacia Biosciences). To produce the Mod(mdg4)-67.2 protein, a clone in the pING14.1 vector (28) was transcribed with SP6 polymerase. GAF protein and its derivatives, produced from the pKH-GAF clone (26) or from PCR fragments obtained from this clone, were transcribed with T7 polymerase. The binding between the bacterially expressed protein  $(1-2 \mu g)$  retained on beads (glutathione Sepharose 4B) or Ni-NTA agarose), and the *in vitro* translated protein was performed in HB buffer  $(50 \text{ mM Hepes}/0.2 \text{ mM EDTA}/1 \text{ mM})$  $DTT/0.5\%$  Nonidet P-40) containing 100 mM NaCl and 5 mg/ml BSA, for  $1-2$  h at room temperature. The beads were

washed five times in HB containing 300 mM NaCl and were loaded on an SDS/PAGE. Gels were fixed and dried before exposure. Two-hybrid assays were carried out by using yeast strain pJ694A, plasmids, and protocols obtained from Clontech. For growth assays, yeasts were plated on nonselective media lacking tryptophan and leucine. After growth, plates were replicated on selective media lacking tryptophan, leucine, histidine, and adenine, and growth was compared. Mod(mdg4)-67.2 and its derivatives were cloned in frame in the bait vector pGBT9. For details of the different subcloning steps, see *Supporting Methods*.

## **Results**

**GAF and Mod(mdg4) Interact in Vivo and in Vitro.** We first asked whether GAF and Mod(mdg4) proteins interact *in vivo* by performing coimmunoprecipitations with nuclear extracts prepared from *Drosophila* SL-2 cells. Fig. 1*A* shows that Mod(mdg4) isoforms are immunoprecipitated by an anti-Mod(mdg4) serum and coimmunoprecipitated by an anti-GAF serum, but not by an anti-polyhomeotic (PH) serum or preimmune sera. This result suggests that GAF and Mod(mdg4) can be present in the same complexes *in vivo* and was confirmed by the reverse experiment: the anti-Mod(mdg4) serum coimmunoprecipitates all GAF isoforms (Fig. 1*B*). This coimmunoprecipitation is reproducible and robust, because greater amounts of GAF are coimmunoprecipitated with Mod(mdg4) than with PH, a protein previously reported to be present in a complex with GAF in embryos (29). Nevertheless, less GAF was coimmunoprecipitated by Mod- (mdg4) antibodies than in the reverse experiment. This result might be due to a different relative abundance of the two proteins in nuclear extracts. However, a quantification of absolute amounts done by comparing the intensities of the bands with fixed amounts of bacterially purified protein isoforms revealed similar levels for the two proteins (data not shown). We therefore decided to analyze their subnuclear distribution.

Recently, the Mod(mdg4)-67.2 isoform has been shown to be present in the nuclear matrix fraction, which is defined experimentally by its resistance to extraction with 2 M NaCl (10). We asked whether GAF is present in the same fraction as Mod- (mdg4) by analyzing nuclear matrix preparations from 0- to 24-h *Drosophila* embryos. Fig. 1*C* shows that a large fraction of GAF resists the 2-M NaCl extraction and is present in the final fraction, similarly to the positive control lamin (10). This finding is even more pronounced for Mod(mdg4) isoforms, which are strongly concentrated in the lamin fraction. In contrast, the Ubx transcription factor is released from chromatin by this procedure. Together, these results indicate that GAF and Mod(mdg4) interact with each other and with nuclear lamin components *in vivo*. They might also partially explain the relatively weak coimmunoprecipitation of GAF by anti-Mod(mdg4) antibodies, because matrix-attached protein complexes containing Mod- (mdg4) isoforms might be incompletely extracted under the conditions used in coimmunoprecipitation experiments.

To determine whether the interaction between GAF and Mod(mdg4) is direct, we investigated their interaction *in vitro*. For this analysis, we used the GAF-519 isoform, which is the predominant form of GAF (30), and the Mod(mdg4)-67.2 isoform, which is the predominant form of Mod(mdg4) and which interacts with  $Su(Hw)$  and is required for the enhancerblocking activity of the Su(Hw) insulator (28, 31). We observed that bacterially expressed GAF is able to interact directly with *in vitro*-translated Mod(mdg4) (Fig. 2*A*). To characterize the domains involved in this interaction, we expressed full-length Mod(mdg4) as a GST fusion protein and used it as bait for different *in vitro*-translated GAF domains (Fig. 2*B*). The fulllength GST-Mod(mdg4) interacts strongly with GAF. This interaction is slightly reduced by removing the C-terminal glutamine-rich (Q-rich) domain from GAF and strongly reduced by



**Fig. 2.** GAF and Mod(mdg4) interact directly *in vitro* and in a two-hybrid assay. The relevant protein domains of the proteins are indicated. (*A*) Interaction between His-tagged GAF and *in vitro*-translated Mod(mdg4)-67.2 and the luciferase negative control. (*B*) GST pull-down by using GST-fused Mod- (mdg4)-67.2 and the Mod(mdg4) BTB domain or GST alone as the negative control. The various GAF derivatives were produced by *in vitro* translation. (*C*) Yeast two-hybrid assay.  $-, +, ++,$  and  $+++$  represent no, weak, middle, and strong interaction, respectively.

removing its BTB domain. Removing both the BTB and the Q-rich domains abolishes the interaction. The GAF BTB domain alone is able to interact with Mod(mdg4). These results show that both the BTB domain and the Q-rich domain of GAF contribute to the interaction with Mod(mdg4). We confirmed this interaction in yeast two-hybrid experiments (Fig. 2*C*). GAF and Mod- (mdg4) interact strongly in this assay, and the interaction is reduced upon removal of the Q-rich domain of GAF, confirming the GST pull-down data. Moreover, this interaction is abolished by deletion of the BTB domain of Mod(mdg4), suggesting that both the GAF as well as the Mod(mdg4) BTB domains are important for the heterologous interaction between the two proteins. Replacing the BTB domain of Mod(mdg4) with that of GAF results in a better interaction of the hybrid protein with full-length GAF or with the GAF variant without Q-rich domain. This result suggests that homodimerization of the GAF BTB domain is preferred to heterodimerization with Mod(mdg4).

**GAF-Binding Sites Promote Insulator Bypass.** We and others have previously observed that the insertion of a second Su(Hw) insulator between an enhancer and a promoter restores enhancer/promoter communication  $(8, 9)$ . We were interested in identifying other sequences that are capable of bypassing the Su(Hw) enhancer-blocking activity. In view of the interaction between GAF-519 and Mod(mdg4)-67.2, we asked whether GAF-binding sites might represent such a sequence.

For this analysis, we used the *miniwhite* gene, involved in the pigmentation of the eye, as a reporter gene, as well as its eye-specific enhancer (Ee). It had previously been shown that one copy of the Su(Hw) insulator efficiently blocks communication between Ee and *miniwhite* (32). We confirmed this result by using the  $(Ee)Y(S)W$  transgene, which contains the Ee



**Fig. 3.** GAF-binding sites neutralize the enhancer-blocking activity of the Su(Hw) insulator. Transgenes are schematically represented above each panel. The transgenic lines are sorted according to their eye colors. Wild-type *miniwhite* expression results in bright red eye color (R), whereas the absence of expression results in white eyes (W). Intermediate levels of pigmentation are defined by eye color ranging from pale yellow (p-Y) to yellow (Y), dark-yellow (d-Y), orange (Or), dark orange (d-Or), brown (Br), or brown-red (Br-R), reflecting increasing levels of *miniwhite* expression. The number of lines in each category is indicated. *miniwhite* expression levels were determined without excision as well as after excision of the functional elements flanked by loxP and frt sites. Analysis of *miniwhite* expression in a wild-type, *Trl<sup>R85</sup>* heterozygous mutant and in a *Mod(mdg4*) homozygous mutant background  $(mod (mdg4)^{u1}$  and  $mod (mdg4)^{T6})$  is indicated (+, Trl, and Mod, respectively). The number of lines in which the eye pigmentation changes after excision of an element or in a mutant background, compared with the original lines, is indicated over the total number of lines. (*A*) Structure of the (Ee)Y(S)W transgene. Arrows indicate the excision of an element to produce the derivatives Y(S)W, (Ee)YW, and YW. Representative eye pictures are shown. (*B*) Structure of the Ee(G)Y(S)W transgene and eye colors of the Ee(G)Y(S)W lines and their derivatives. (*C*) Structure of the (Ee)(G)YW transgene and eye colors of the (Ee)(G)YW lines and their derivatives.

enhancer separated from *miniwhite* (W) by the *yellow* marker gene (Y) and a Su(Hw) insulator (S) (Fig. 3*A*). The enhancer is flanked by frt sites, allowing its excision by crossing the transgenic flies with flies expressing the FLP recombinase. Similarly, the Su(Hw) insulator is flanked by loxP sites and can be excised by the action of the CRE recombinase. Eleven independent transgenic (Ee)Y(S)W lines were obtained. Their eye color varies from pale-yellow to brown. Excision of the Su(Hw) insulator increased *miniwhite* expression in all 11 lines [compare (Ee)Y(S)W and (Ee)YW], indicating that the insulator blocks the Ee enhancer. This block is very efficient, because the excision of Ee from the transgene containing the Su(Hw) insulator did not lighten the eye pigmentation [compare (Ee)Y(S)W and Y(S)W], whereas it did in all lines in which the insulator had already been excised [compare (Ee)YW and YW].

We next tested the consequence of inserting an array of GAF-binding sites between the Ee and the Su(Hw) insulator. This array was obtained by duplication of a fragment from the *hsp70* promoter region that contains four GAF-binding sites that are bound by GAF *in vivo* (33, 34). We constructed the Ee- (G)Y(S)W transgene containing the Ee enhancer separated from *miniwhite* by the *yellow* gene, which is bordered at its 5' end by the GAF array  $(G)$  and at its 3' end by the Su $(Hw)$  insulator (S) (Fig. 3*B*). The cluster of GAF-binding sites is flanked by frt sites, and the Su(Hw) insulator is flanked by loxP sites. Twelve independent transgenic Ee(G)Y(S)W lines were obtained, and derivatives lacking either the GAF-binding sites [EeY(S)W], the Su(Hw) insulator [Ee(G)YW], or both (EeYW), were generated by crossing with flies expressing the appropriate recombinases. For each line, *miniwhite* expression was studied in a wild-type background as well as in  $Tr l^{R85}/+$  and  $mod(mdg4)^{u1}$  or  $mod(mdg4)^{T6}$  mutant backgrounds.  $Trl^{R85}$  is a partial deletion of the *Trl* gene and is a putative null allele (21).  $mod(mdg4)^{u1}$  and  $mod(m\bar{d}g4)^{T6}$  are two mutations that disrupt the C-terminal part of the Mod(mdg4)-67.2 isoform only (6, 35). Because the same results were obtained with either alleles in all experiments, we will refer to *mod*(*mdg4*) mutant background for simplicity.  $E_e(G)Y(S)W$  lines show an eye color ranging from orange to red, which is significantly darker than the pigmentation observed in the previous  $(Ee)Y(S)W$  lines. This result suggests that the GAF-binding sites neutralize the enhancer-blocking activity of the Su(Hw) insulator. Indeed, excision of the GAF-binding sites induces a strong reduction of *miniwhite* expression in all lines [compare  $E_e(G)Y(S)W$  and  $E_eY(S)W$ ], indicating that the excision restores the ability of the Su(Hw) insulator to block communication between the Ee enhancer and *miniwhite*. In contrast, *yellow* expression was strong in all tissues and all lines tested. In particular, no variation was observed upon excision of GAF-binding sites (data not shown). Thus, the enhancerblocking activity, as well as the bypass activity, is seen only when the Su(Hw) insulator is placed between enhancer and promoter.

In a *mod(mdg4*) mutant background, expression of *miniwhite* increased in 9 of 12 of the EeY(S)W lines, demonstrating that the Su(Hw) insulator blocks communication between the Ee enhancer and the *miniwhite* promoter through the action of the Mod(mdg4) protein. Interestingly, placing the  $E_e(G)Y(S)W$ lines in a  $mod(mdg4)$  or  $Trl^{R85}/+$  mutant background resulted in a decrease in eye pigmentation in the majority of the lines  $(10/12)$ and  $9/12$ , respectively). This result indicates that both GAF and Mod(mdg4) proteins are involved in the bypass of the Su(Hw) insulator. Excision of the insulator from the construct renders the lines insensitive to *Trl* and *mod(mdg4*) mutations as well as to GAF-binding site excision [Fig. 3*B*, Ee(G)W and EeYW constructs]. It should be noted here that excision of the insulator induced full *miniwhite* activation [compare the difference between EeY(S)W and EeYW, inducing full loss of enhancer blocking], whereas the Ee is still partially blocked upon mutation of *mod(mdg4*) [compare EeY(S)W in wild-type or *mod(mdg4*) mutant backgrounds]. This result suggests that the absence of the Mod(mdg4)-67.2 protein isoform might not completely abolish the function of the Su(Hw) insulator as such, although it is essential for the interaction with GAF sites that is responsible for insulator bypass.

One might postulate that the presence of GAF-binding sites stimulates *miniwhite* transcription in a manner that is not totally blocked by the Su(Hw) insulator. To test this possibility, we constructed the transgene  $(Fe)(G)YW$ , which contains the Ee enhancer flanked by frt sites, the cluster of GAF-binding sites flanked by loxP sites, and the *yellow* and *miniwhite* genes (Fig. 3*C*). We analyzed the eye color of 14 independent insertions. We



**Fig. 4.** GAF is involved in partial neutralization of the Su(Hw) enhancerblocking activity by *Mcp*. The structure of the Ee(M)Y(S)W transgene is depicted. The *Mcp* element contains two GAF-binding sites (indicated as red bars). *miniwhite* expression was analyzed as described in Fig. 3.

observed that the excision of the GAF-binding sites did not significantly reduce the eye pigmentation of the transgenic flies, regardless of whether or not the Ee enhancer is present in the construct [Fig. 3*C*, compare (Ee)(G)YW with (Ee)YW and (G)YW with YW]. This result demonstrates that the mere presence of GAF-binding sites in the transgene does not stimulate *miniwhite* expression (Fig. 3 *B* and *C*). Moreover, GAFbinding sites do not have enhancer-blocking activity *per se*, because their excision does not induce an increase in *miniwhite* expression. Taken together, our results show that the interposition of GAF-binding sites between the Ee enhancer and the Su(Hw) insulator allows the insulator's enhancer-blocking activity to be bypassed, restoring communication between Ee and *miniwhite*.

**The Mcp Element Allows Bypass of the Su(Hw) Insulator.** We next tested whether a single-copy natural element can neutralize the enhancer-blocking activity of the Su(Hw) insulator. We used a 690-bp *Mcp* sequence from the BX-C. Genetic analyses indicate that this element behaves as a boundary separating the *iab-4* and *iab-5* regulatory domains in the BX-C (36). This 690-bp sequence contains the MCP138 element, which is sufficient to maintain silencing of a transgene in embryos and larvae (20). The MCP138 element contains two GAF-binding sites, and both the GAF protein and the GAF-binding sites are required for its silencing activity (20).

We inserted the 690-bp *Mcp* element between the Ee enhancer and the *yellow* gene in (Ee)Y(S)W to produce the (Ee)MY(S)W transgene (Fig. 4). In all six transgenic (Ee)MY(S)W lines, the pigmentation observed in bristle, wing, and body is variegated and independent on excision of functional elements within the construct (data not shown). This finding suggests that *Mcp* represses the *yellow* promoter. At the same time, expression of *miniwhite* is significantly stronger than in the (Ee)Y(S)W lines, suggesting that the presence of *Mcp* allows the Su(Hw) insulator to be bypassed by the eye enhancer. The eye enhancer activates the *miniwhite* promoter in the (Ee)MY(S)W transgene, as evidenced by the strong reduction in eye pigmentation seen upon excision of the Ee element [Fig. 4, compare (Ee)MY(S)W and MY(S)W]. Thus, *Mcp* partially neutralizes the enhancerblocking activity of the Su(Hw) insulator. Similar results were obtained when the *Mcp* element was placed in a reverse orientation (data not shown). As observed with the  $E_e(G)Y(S)W$ construct, placing the (Ee)MY(S)W transgenes in a *mod(mdg4*) mutant background decreases *miniwhite* expression in all of the lines. A similar, although weaker, effect was observed in the *Trl*<sup>R85</sup> mutant background in 4/6 lines. These results indicate that both Mod(mdg4) and GAF proteins are involved in the neutralization of the Su(Hw) insulator by *Mcp*.

We observed that excision of the insulator in the  $(Ee)MY(S)W$ derivatives decreases the eye pigmentation of the flies, both when the enhancer is present [(Ee)MYW lines] and when it has been excised (MYW lines), indicating that *Mcp* silences *miniwhite* in the absence of the Su(Hw) insulator. In other words, the silencing activity of *Mcp* is blocked when the Su(Hw) insulator is present in the transgene. These results suggest that the interaction between *Mcp* and the Su(Hw) insulator allows the enhancer-blocking activity of the insulator to be bypassed in a manner compatible with blocking of the silencing activity of *Mcp*. The lack of insulator bypass by the *Mcp* silencer might depend on the fact that the silencer overlaps the chromatin boundary in *Mcp*. It is conceivable that the interaction of GAF with Mod(mdg4) might trap the *Mcp* silencer close to the insulator and thus prevent silencing to cross the Su(Hw) barrier.

## **Discussion**

In this study, we show that inserting either a cluster of GAFbinding sites or the *Mcp* boundary between an enhancer and the Su(Hw) insulator neutralizes the enhancer-blocking activity of the insulator and restores communication between the upstream enhancer and the downstream promoter. These results are reminiscent of what is observed when two copies of the Su(Hw) insulator are placed in tandem between an enhancer and a reporter gene: both insulators are bypassed. We propose that the GAF-binding sites and the *Mcp* element can pair with the Su(Hw) insulator and neutralize its enhancer-blocking activity. Given the direct interaction between GAF and Mod(mdg4) proteins reported here, this pairing could be mediated by interactions between the GAF protein bound to the GAFbinding sites and the Mod(mdg4) protein bound to the insulator by means of its interaction with the Su(Hw) protein. Such pairing would loop out the sequences between the GAF-binding sites and the insulator, bringing the upstream enhancer and downstream promoter into close proximity to each other.

Several BTB domain-containing proteins have been implicated in enhancer/promoter communication and loop formation. The GAF protein itself can form oligomers through its BTB domain (37, 38) and can link separate DNA fragments containing GAGA sites *in vitro* (39). These interactions have been proposed as being involved in enhancer/promoter communication by bringing these elements into close proximity to each other. Our results provide evidence that interactions between different BTB-containing proteins can promote loop formation, and that such interactions can be involved in the regulation of insulator function and/or the regulation of enhancer/promoter communication.

Our results also suggest that a GAF- and Mod(mdg4) dependent interaction between the *Mcp* boundary and the Su(Hw) insulator leads to the bypass of the Su(Hw) insulator. Recently, two independent studies (40, 41) examined possible interactions between homologous and heterologous *Drosophila* insulator pairs in transgenic assays. Except for the pair of Su(Hw) insulators, none of the combinations tested led to insulator bypass. However, there is evidence for insulator bypass in at least two cases in *Drosophila*. A first set of data strongly suggests that a *gypsy* insulator inserted within an intron of the *yellow* gene can be bypassed by downstream enhancers, due to the presence of a second endogenous insulator located between the 3' end of the gene and the enhancers (42). This endogenous insulator was shown to be capable of enhancer blocking and is bound by the Su(Hw) protein *in vivo*. Its insulator function, however, was shown to be only moderately dependent on Su(Hw), suggesting that other proteins may participate in its enhancer-blocking activity and in pairing with the *gypsy* insulator.

A second case of insulator bypass has been described in the BX-C. At this locus, *Abd-B* expression is regulated by a series of regulatory regions, called *iab*-5, *iab*-6, *iab*-7, and *iab*-8,9, which are located up to 50 kb downstream of the *Abd-B* transcription unit and which are believed to be separated from each other by boundaries (reviewed in ref. 11). The *Fab-7* and *Fab-8* boundaries flank the *iab-7* domain, which is involved in *Abd-B* activation in parasegment 12. In this parasegment, *iab-7* has to overcome the *Fab-8* boundary to activate *Abd-B*. Zhou and Levine (43) identified a sequence, called the promoter-targeting sequence (PTS), that is located near the *Fab-8* boundary within the *iab-7* domain and that promotes bypass of *Fab-8*. In transgenesis, the PTS is able to neutralize the enhancer-blocking activity of both the *Fab-8* boundary and the Su(Hw) insulator when it is inserted between the enhancer and the promoter (43, 44). In addition, mutations in the PTS within the BX-C produce homeotic transformations that reveal a lack of *Abd-B* activation by *iab-7*, suggesting that the enhancer is blocked by the *Fab-8* boundary in the absence of PTS.

Our data are compatible with GAF sites or the *Mcp* element behaving in a manner similar to the PTS element of the BX-C, although the PTS is molecularly poorly characterized and thus it is not possible to conclude on how it acts. This work provides direct evidence for a bypass of the Su(Hw) insulator that is induced by heterologous *Drosophila* DNA sequences and identifies the protein pair  $GAF/Mod(mdg4)$  as responsible for the bypass. Neither a cluster of GAF-binding sites nor the *Mcp* boundary have been previously tested in combination with the Su(Hw) insulator in transgenic assays. No Su(Hw) insulator bypass was found, however, with two other elements that also bind GAF, the SF1 and the *Fab-7* boundaries (41). This result may reflect an interference with the GAF/Mod(mdg4) interaction by other proteins bound to the SF1 or *Fab-7* boundaries. For instance, although our data demonstrate a role for GAF in

- 1. West, A. G., Gaszner, M. & Felsenfeld, G. (2002) *Genes Dev*. **16,** 271–288.
- 2. Blanton, J., Gaszner, M. & Schedl, P. (2003) *Genes Dev*. **17,** 664–675.
- 3. Ishii, K., Arib, G., Lin, C., Van Houwe, G. & Laemmli, U. K. (2002) *Cell* **109,** 551–562.
- 4. Yusufzai, T. M., Tagami, H., Nakatani, Y. & Felsenfeld, G. (2004) *Mol*. *Cell* **13,** 291–298.
- 5. Spana, C., Harrison, D. A. & Corces, V. G. (1988) *Genes Dev*. **2,** 1414–1423.
- 6. Gerasimova, T. I., Gdula, D. A., Gerasimov, D. V., Simonova, O. & Corces, V. G. (1995) *Cell* **82,** 587–597.
- 7. Gerasimova, T. I. & Corces, V. G. (1998) *Cell* **92,** 511–521.
- 8. Muravyova, E., Golovnin, A., Gracheva, E., Parshikov, A., Belenkaya, T., Pirrotta, V. & Georgiev, P. (2001) *Science* **291,** 495–498.
- 9. Cai, H. N. & Shen, P. (2001) *Science* **291,** 493–495.
- 10. Byrd, K. & Corces, V. G. (2003) *J*. *Cell Biol*. **162,** 565–574.
- 11. Mihaly, J., Hogga, I., Barges, S., Galloni, M., Mishra, R. K., Hagstrom, K., Muller, M., Schedl, P., Sipos, L., Gausz, J., *et al*. (1998) *Cell Mol*. *Life Sci*. **54,** 60–70.
- 12. Belozerov, V. E., Majumder, P., Shen, P. & Cai, H. N. (2003) *EMBO J*. **22,** 3113–3121.
- 13. Ohtsuki, S. & Levine, M. (1998) *Genes Dev*. **12,** 3325–3330.
- 14. O'Donnell, K. H., Chen, C. T. & Wensink, P. C. (1994) *Mol*. *Cell*. *Biol*. **14,** 6398–6408.
- 15. Bantignies, F., Grimaud, C., Lavrov, S., Gabut, M. & Cavalli, G. (2003) *Genes Dev*. **17,** 2406–2420.
- 16. Muller, M., Hagstrom, K., Gyurkovics, H., Pirrotta, V. & Schedl, P. (1999) *Genetics* **153,** 1333–1356.
- 17. Strutt, H., Cavalli, G. & Paro, R. (1997) *EMBO J*. **16,** 3621–3632.
- 18. O'Donnell, K. H. & Wensink, P. C. (1994) *Nucleic Acids Res*. **22,** 4712–4718. 19. Mishra, R. K., Mihaly, J., Barges, S., Spierer, A., Karch, F., Hagstrom, K., Schweinsberg, S. E. & Schedl, P. (2001) *Mol*. *Cell*. *Biol*. **21,** 1311–1318.
- 20. Busturia, A., Lloyd, A., Bejarano, F., Zavortink, M., Xin, H. & Sakonju, S. (2001) *Development (Cambridge*, *U*.*K*.*)* **128,** 2163–2173.
- 21. Farkas, G., Gausz, J., Galloni, M., Reuter, G., Gyurkovics, H. & Karch, F. (1994) *Nature* **371,** 806–808.
- 22. Lehmann, M. (2004) *Trends Genet*. **20,** 15–22.
- 23. Wilkins, R. C. & Lis, J. T. (1997) *Nucleic Acids Res*. **25,** 3963–3968.
- 24. Benyajati, C., Mueller, L., Xu, N., Pappano, M., Gao, J., Mosammaparast, M., Conklin, D., Granok, H., Craig, C. & Elgin, S. (1997) *Nucleic Acids Res*. **25,** 3345–3353.

insulator neutralization, they do not rule out the possible involvement of other GAGA-motif-binding proteins, such as Pipsqueak (Psq) (45, 46), which might play a role at a subset of the GAF-binding motifs. Moreover, both the SF1 and the *Fab-7* insulators are complex elements that may be regulated by specific factors. This is probably the reason why two copies of each of these two insulators are also not bypassed, and it will be interesting to isolate DNA sequences and proteins that promote or counteract the bypass phenomenon. Finally, it has been shown that Su(Hw) insulator activity depends both on insulator strength and on the strength of the elements it counteracts (47, 48). Such a precise balance may be necessary to achieve bypass between two heterologous insulators. Therefore, the bypass of insulators is not a universal phenomenon but is instead involved in the regulation of a subset of genomic loci, depending upon the intrinsic features of the different regulatory DNA sequences and associated factors involved. In this way, at least some characterized insulators may not behave as immutable barriers, but rather participate in the dynamic regulation of gene expression during development and differentiation.

We thank Donna Arndt-Jovin, Rainer Dorn, Yacine Graba, and Florence Maschat for their generous gift of antibodies. We thank Dale Dorsett (Saint Louis University School of Medicine, St. Louis, MO) for expression clones of Mod(mdg4) derivatives, and Peter Becker (University of Munich, Munich) and Pamela Geyer for DNA clones. F.J. was supported by a postdoctoral fellowship of the Fondation Schlumberger pour L'Éducation et la Recherche (FSER). G.C. was supported by grants from the Centre National de la Recherche Scientifique, the Human Frontier Science Program Organization, and the Association pour la Recherche sur le Cancer. P.G. was supported by the Molecular and Cellular Biology program of the Russian Academy of Science, by the Volkswagen-Stiftung Foundation (Federal Republic of Germany), and by an International Research Scholar award from the Howard Hughes Medical Institute.

- 25. Albagli, O., Dhordain, P., Deweindt, C., Lecocq, G. & Leprince, D. (1995) *Cell Growth Differ*. **6,** 1193–1198.
- 26. Agianian, B., Leonard, K., Bonte, E., Van der Zandt, H., Becker, P. B. & Tucker, P. A. (1999) *J*. *Mol*. *Biol*. **285,** 527–544.
- 27. Fisher, P. A. & Blobel, G. (1983) *Methods Enzymol*. **96,** 589–596.
- 28. Gause, M., Morcillo, P. & Dorsett, D. (2001) *Mol*. *Cell*. *Biol*. **21,** 4807–4817.
- 29. Poux, S., Melfi, R. & Pirrotta, V. (2001) *Genes Dev*. **15,** 2509–2514.
- 30. Soeller, W. C., Oh, C. E. & Kornberg, T. B. (1993) *Mol*. *Cell*. *Biol*. **13,** 7961–7970.
- 31. Ghosh, D., Gerasimova, T. I. & Corces, V. G. (2001) *EMBO J*. **20,** 2518–2527.
- 32. Roseman, R. R., Pirrotta, V. & Geyer, P. K. (1993) *EMBO J*. **12,** 435–442.
- 33. O'Brien, T., Wilkins, R. C., Giardina, C. & Lis, J. T. (1995) *Genes Dev*. **9,** 1098–1110.
- 34. Tsukiyama, T., Becker, P. B. & Wu, C. (1994) *Nature* **367,** 525–532.
- 35. Mongelard, F., Labrador, M., Baxter, E. M., Gerasimova, T. I. & Corces, V. G. (2002) *Genetics* **160,** 1481–1487.
- 36. Karch, F., Galloni, M., Sipos, L., Gausz, J., Gyurkovics, H. & Schedl, P. (1994) *Nucleic Acids Res*. **22,** 3138–3146.
- 37. Espinas, M. L., Jimenez-Garcia, E., Vaquero, A., Canudas, S., Bernues, J. & Azorin, F. (1999) *J*. *Biol*. *Chem*. **274,** 16461–16469.
- 38. Katsani, K. R., Hajibagheri, M. A. & Verrijzer, C. P. (1999) *EMBO J*. **18,** 698–708.
- 39. Mahmoudi, T., Katsani, K. R. & Verrijzer, C. P. (2002) *EMBO J*. **21,** 1775–1781.
- 40. Kuhn, E. J., Viering, M. M., Rhodes, K. M. & Geyer, P. K. (2003) *EMBO J*. **22,**
- 2463–2471. 41. Majumder, P. & Cai, H. N. (2003) *Proc*. *Natl*. *Acad*. *Sci*. *USA* **100,** 5223–5228.
- 42. Parnell, T. J., Viering, M. M., Skjesol, A., Helou, C., Kuhn, E. J. & Geyer, P. K.
- (2003) *Proc*. *Natl*. *Acad*. *Sci*. *USA* **100,** 13436–13441.
- 43. Zhou, J. & Levine, M. (1999) *Cell* **99,** 567–575.
- 44. Lin, Q., Wu, D. & Zhou, J. (2003) *Development (Cambridge*, *U*.*K*.*)* **130,** 519–526.
- 45. Huang, D. H., Chang, Y. L., Yang, C. C., Pan, I. C. & King, B. (2002) *Mol*. *Cell*. *Biol*. **22,** 6261–6271.
- 46. Schwendemann, A. & Lehmann, M. (2002) *Proc*. *Natl*. *Acad*. *Sci*. *USA* **99,** 12883–12888.
- 47. Scott, K. C., Taubman, A. D. & Geyer, P. K. (1999) *Genetics* **153,** 787–798.
- 48. Cai, H. N., Zhang, Z., Adams, J. R. & Shen, P. (2001) *Development (Cambridge*, *U*.*K*.*)* **128,** 4339–4347.

L<br>NAS